Label: SUMAXIN CLEANSING PADS- sulfacetamide sodium and sulfur cloth
SUMAXIN CP- sulfacetamide sodium and sulfur kit
- NDC Code(s): 43538-100-60, 43538-101-60
- Packager: Medimetriks Pharmaceuticals, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: unapproved drug other
DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Drug Label Information
Updated December 15, 2023
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
- SPL UNCLASSIFIED SECTION
-
DESCRIPTION
Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:
Each pad of Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads is coated with a cleanser-based formulation. Each gram of this cleanser-based formulation contains 100 mg of Sodium Sulfacetamide and 40 mg of Sulfur. The cleanser base consists of: aloe, butylated hydroxytoluene, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glycerin, glyceryl stearate/PEG-100 stearate, green tea, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium lauryl sulfoacetate, sodium thiosulfate, stearyl alcohol.
-
CLINICAL PHARMACOLOGY
The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.
- INDICATIONS
-
CONTRAINDICATIONS
Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are not to be used by patients with kidney disease.
-
WARNINGS
Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.
FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep container tightly closed.
-
PRECAUTIONS
General
If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.
Information for Patients
Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.
Carcinogenesis, Mutagenesis and Impairment of Fertility
Long-term studies in animals have not been performed to evaluate carcinogenic potential.
PREGNANCY
Category C
Animal reproduction studies have not been conducted with Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads. It is also not known whether Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads should be given to a pregnant woman only if clearly needed.
NURSING MOTHERS
It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are administered to a nursing woman.
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- SPL UNCLASSIFIED SECTION
- PRINCIPAL DISPLAY PANEL - 60 Pad Carton
- PRINCIPAL DISPLAY PANEL - Kit Carton
-
INGREDIENTS AND APPEARANCE
SUMAXIN CLEANSING PADS
sulfacetamide sodium and sulfur clothProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43538-100 Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Sulfacetamide sodium (UNII: 4NRT660KJQ) (sulfacetamide - UNII:4965G3J0F5) Sulfacetamide sodium 100 mg in 1 g Sulfur (UNII: 70FD1KFU70) (sulfur - UNII:70FD1KFU70) Sulfur 40 mg in 1 g Inactive Ingredients Ingredient Name Strength aloe (UNII: V5VD430YW9) butylated hydroxytoluene (UNII: 1P9D0Z171K) cetyl alcohol (UNII: 936JST6JCN) disodium oleamido monoethanolamine sulfosuccinate (UNII: 5M1101WGSY) edetate disodium (UNII: 7FLD91C86K) glycerin (UNII: PDC6A3C0OX) green tea leaf (UNII: W2ZU1RY8B0) methylparaben (UNII: A2I8C7HI9T) propylparaben (UNII: Z8IX2SC1OH) water (UNII: 059QF0KO0R) sodium cocoyl isethionate (UNII: 518XTE8493) sodium lauryl sulfoacetate (UNII: D0Y70F2B9J) sodium thiosulfate (UNII: HX1032V43M) stearyl alcohol (UNII: 2KR89I4H1Y) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:43538-100-60 60 in 1 CARTON 01/01/2009 1 3.7 g in 1 PACKET; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date UNAPPROVED DRUG OTHER 01/01/2009 SUMAXIN CP
sulfacetamide sodium and sulfur kitProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43538-101 Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:43538-101-60 1 in 1 CARTON 08/01/2011 Quantity of Parts Part # Package Quantity Total Product Quantity Part 1 60 PACKET 222 g Part 2 1 BOTTLE, PUMP 454 g Part 1 of 2 SUMAXIN CLEANSING PADS
sulfacetamide sodium and sulfur clothProduct Information Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength sulfacetamide sodium (UNII: 4NRT660KJQ) (sulfacetamide - UNII:4965G3J0F5) sulfacetamide sodium 100 mg in 1 g sulfur (UNII: 70FD1KFU70) (sulfur - UNII:70FD1KFU70) sulfur 40 mg in 1 g Inactive Ingredients Ingredient Name Strength aloe (UNII: V5VD430YW9) butylated hydroxytoluene (UNII: 1P9D0Z171K) cetyl alcohol (UNII: 936JST6JCN) disodium oleamido monoethanolamine sulfosuccinate (UNII: 5M1101WGSY) edetate disodium (UNII: 7FLD91C86K) glycerin (UNII: PDC6A3C0OX) green tea leaf (UNII: W2ZU1RY8B0) methylparaben (UNII: A2I8C7HI9T) propylparaben (UNII: Z8IX2SC1OH) water (UNII: 059QF0KO0R) sodium cocoyl isethionate (UNII: 518XTE8493) sodium lauryl sulfoacetate (UNII: D0Y70F2B9J) sodium thiosulfate (UNII: HX1032V43M) stearyl alcohol (UNII: 2KR89I4H1Y) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 60 in 1 CARTON 1 3.7 g in 1 PACKET; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Unapproved drug other 01/01/2009 Part 2 of 2 REHYLA WASH
bath soaps and body washes [personal cleanliness]Product Information Route of Administration TOPICAL Other Ingredients Ingredient Kind Ingredient Name Quantity INGR water (UNII: 059QF0KO0R) INGR glyceryl monostearate (UNII: 230OU9XXE4) INGR glycerin (UNII: PDC6A3C0OX) INGR cetyl alcohol (UNII: 936JST6JCN) INGR disodium oleamido mipa-sulfosuccinate (UNII: 0MBZ20845F) INGR cholesterol (UNII: 97C5T2UQ7J) INGR disodium laureth sulfosuccinate (UNII: D6DH1DTN7E) INGR helianthus annuus seed wax (UNII: 42DG15CHXV) INGR caprylyl glycol (UNII: 00YIU5438U) INGR propylene glycol (UNII: 6DC9Q167V3) INGR phenoxyethanol (UNII: HIE492ZZ3T) INGR sodium cocoyl isethionate (UNII: 518XTE8493) INGR cocamidopropyl betaine (UNII: 5OCF3O11KX) INGR sodium methyl cocoyl taurate (UNII: JVL98CG53G) INGR C13-14 isoparaffin (UNII: E4F12ROE70) INGR sodium chloride (UNII: 451W47IQ8X) INGR niacinamide (UNII: 25X51I8RD4) INGR edetate disodium (UNII: 7FLD91C86K) INGR hexylene glycol (UNII: KEH0A3F75J) INGR laureth-7 (UNII: Z95S6G8201) INGR chamaemelum nobile flower (UNII: O2T154T6OG) INGR hyaluronate sodium (UNII: YSE9PPT4TH) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 1 in 1 CARTON 1 454 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Cosmetic 08/01/2011 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Unapproved drug other 08/01/2011 Labeler - Medimetriks Pharmaceuticals, Inc. (019903816) Establishment Name Address ID/FEI Business Operations Marketing Advertising Promotions, Inc. 797063526 PACK(43538-101)